REPLIGEN CORP
RGEN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RGEN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RGEN
REPLIGEN CORP is a biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders and commercializing specialty pharmaceutical products, with a strategy of funding R&D through product sales.
Key risk: Sustained operating losses
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$9.95B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
REPLIGEN CORP is a biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders and commercializing specialty pharmaceutical products, with a strategy of funding R&D through product sales.
- REPLIGEN CORP focuses on developing novel therapeutics for CNS diseases such as schizophrenia, obsessive-compulsive disorder, bipolar disorder, and neurodegeneration [sec · filed 2005-06-14].
- The company generates revenue from commercial product sales, which partially fund its proprietary drug development programs [sec · filed 2004-06-14].
- As of 2026-06-30, REPLIGEN reported cash & equivalents of $608.8M, total revenue of $204.1M, net income of $5.0M, shareholders' equity of $2,061.7M, and total debt of $551.0M [sec].
- The company has incurred losses since its founding in 1981 and expects to continue operating losses for the foreseeable future [sec · filed 2004-06-14].
- REPLIGEN's business strategy includes maintaining full commercial rights to product candidates through proof-of-principle clinical studies, then potentially seeking corporate partners for further development [sec · filed 2004-06-14].
What works
- REPLIGEN has a diversified pipeline targeting multiple CNS indications, including schizophrenia, obsessive-compulsive disorder, bipolar disorder, and neurodegeneration [sec · filed 2005-06-14].
- The company funds its R&D through profits from commercial product sales, reducing reliance on external financing for early-stage development [sec · filed 2004-06-14].
- REPLIGEN's strategy of retaining full commercial rights through proof-of-principle studies allows it to maximize potential value before partnering [sec · filed 2004-06-14].
What to weigh
- REPLIGEN has incurred losses each year since its founding in 1981 and expects to continue operating losses for the foreseeable future [sec · filed 2004-06-14].
- The company faces intense competition from larger pharmaceutical and biotechnology firms with greater financial, manufacturing, marketing, and R&D resources [sec · filed 2004-06-14].
- REPLIGEN's accumulated deficit was $157.5 million as of a historical filing, reflecting sustained unprofitability [sec · filed 2005-06-14].
- The company's future capital requirements depend on uncertain factors such as clinical success, R&D progress, and ability to sustain product sales [sec · filed 2005-06-14].
From the filings
Quoted directly from source documents.
REPLIGEN focuses on CNS therapeutics and commercial products
“We are a biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. A number of drug development programs are currently being conducted to evaluate our naturally occurring drug candidates in diseases such as schizophrenia, obsessive-compulsive disorder, bipolar disorder and neurodegeneration. In addition, we sell two commercial products”
SEC filings · June 14, 2005
REPLIGEN funds R&D through product sales
“We partially fund the development of our proprietary therapeutic product candidates with the profits derived from the sales of our specialty pharmaceutical products.”
SEC filings · June 14, 2004
REPLIGEN has incurred losses since founding
“We have incurred losses in each year since our founding in 1981. We expect to continue to incur operating losses for the foreseeable future.”
SEC filings · June 14, 2004
REPLIGEN faces competition from larger firms
“Pharmaceutical and mature biotechnology companies have substantially greater financial, manufacturing, marketing, research and development resources than we have.”
SEC filings · June 14, 2004
Risks & what to watch (4)›
Key risks
- Sustained operating losses — REPLIGEN has incurred losses since 1981 and expects continued losses, with an accumulated deficit of $157.5M historically [sec · filed 2005-06-14].
- Intense competition — Larger pharmaceutical and biotech firms with greater resources could make REPLIGEN's products obsolete [sec · filed 2004-06-14].
- Dependence on product sales — Revenue from product sales is insufficient to cover R&D costs, requiring additional capital for drug development [sec · filed 2005-06-14].
- Uncertain capital requirements — Future capital needs depend on clinical success, R&D progress, and ability to sustain sales, creating financial uncertainty [sec · filed 2005-06-14].
What to watch
- Monitor REPLIGEN's ability to sustain and grow product sales to fund R&D [sec · filed 2004-06-14].
- Track progress of clinical trials for CNS candidates in schizophrenia, OCD, bipolar disorder, and neurodegeneration [sec · filed 2005-06-14].
- Watch for potential corporate partnerships after proof-of-principle studies [sec · filed 2004-06-14].
- Observe changes in cash position and accumulated deficit in future filings [sec].
Sources: SEC filings · Generated August 25, 2026 · How we verify sources →
Run REPLIGEN CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available REPLIGEN CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.40 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
440
Total value held
$7.29B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 5,993,054 | $706.1M |
| vanguard capital management llc | 4,793,022 | $564.7M |
| fmr llc | 2,886,786 | $340.1M |
| united capital financial advisors, llc | 2,773,980 | $326.8M |
| vanguard portfolio management llc | 2,305,094 | $271.6M |
| state street corp | 1,777,285 | $209.4M |
| bank of new york mellon corp | 1,531,402 | $180.4M |
| maverick capital ltd | 1,518,805 | $178.9M |
| massachusetts financial services co /ma/ | 1,397,515 | $164.7M |
| invesco ltd. | 1,278,255 | $150.6M |
Showing top 10 of 440 institutional holders of REPLIGEN CORP. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 9.9%
- Days to cover
- 6.4
- Shares short
- 5,556,333
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RGEN short interestGovernance
Frequently asked questions
What is the AI investment thesis for REPLIGEN CORP?
REPLIGEN CORP is a biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders and commercializing specialty pharmaceutical products, with a strategy of funding R&D through product sales.
Who is the CEO of REPLIGEN CORP?
Mr. Olivier Loeillot is the chief executive officer of REPLIGEN CORP (RGEN).
Where is REPLIGEN CORP headquartered?
REPLIGEN CORP (RGEN) is headquartered in Waltham, MA, United States.
What therapeutic areas does REPLIGEN CORP focus on?
REPLIGEN CORP develops therapies across Oncology, Gene Therapy, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.